Passed
407 Yea4 Nay19 Not voting2/3 required
HR-747-119
Received in the Senate and Read twice and referred to the Committee on Banking, Housing, and Urban Affairs.
Sponsored by Andy Barr (R-KY)
What it does
This bill would expand the existing Fentanyl Sanctions Act to explicitly include Chinese companies and senior Chinese government officials as sanctionable "foreign opioid traffickers" if they produce or distribute synthetic opioids or precursor chemicals and fail to take steps to prevent trafficking. It would also require the President to submit annual written evaluations to Congress when using emergency economic powers (IEEPA) to address drug trafficking emergencies, and would require cost-benefit analysis before issuing related regulations. Sanctions would not apply to the importation of physical goods.
Who benefits
Americans affected by the fentanyl crisis, including families of overdose victims and communities with high overdose rates. Law enforcement agencies that would gain additional legal tools to pressure Chinese chemical suppliers. U.S. drug treatment and public health systems that could see reduced fentanyl supply. Congressional oversight committees that would receive new mandatory reporting from the executive branch. Domestic chemical manufacturers who compete with Chinese suppliers.
Who is hurt
Chinese chemical and pharmaceutical companies that could face asset freezes and U.S. market exclusions. Senior Chinese government officials who could be personally sanctioned. U.S. businesses that rely on Chinese-sourced chemical precursors for legitimate manufacturing. Diplomatic and trade relations with China broadly, which could face retaliatory measures affecting unrelated industries. U.S. importers and supply chains dependent on Chinese chemical exports.
Supporters argue
Supporters argue that China is the primary source of fentanyl precursor chemicals — the DEA has identified Chinese suppliers as the dominant upstream source for the synthetic opioids that killed over 74,000 Americans in 2023 alone. They contend that expanding the Fentanyl Sanctions Act to name Chinese entities and officials directly, and requiring accountability for "intentional inaction," closes a loophole that has allowed Chinese officials to avoid consequences by claiming ignorance of downstream trafficking.
Opponents argue
Opponents argue that sanctions on Chinese officials and companies risk triggering retaliatory economic measures at a time of already-elevated U.S.-China trade tensions, potentially harming American industries and consumers far beyond the drug policy context. They contend that prior fentanyl-related sanctions on Chinese entities — including Treasury's 2019 designations — produced limited measurable reductions in fentanyl supply, suggesting that unilateral sanctions alone are insufficient without coordinated international enforcement and Chinese government cooperation.
Constitutional context
The Foreign Commerce Clause (Art. I, §8, cl. 3) and IEEPA grant Congress and the President broad authority to impose economic sanctions on foreign entities. The bill's IEEPA amendments add congressional reporting requirements, touching the boundary between executive emergency powers and legislative oversight — an area where courts have generally deferred to the political branches but where IEEPA's scope is subject to ongoing debate.
Checks and balances
The executive branch (President and Treasury/OFAC) gains expanded sanctioning authority over Chinese entities; Congress gains new oversight through mandatory annual evaluations and cost-benefit reporting requirements under IEEPA, partially rebalancing emergency economic powers toward legislative accountability.
Historical precedent
The Treasury Department designated several Chinese nationals and entities under the Fentanyl Sanctions Act in 2019–2020, representing the first use of that authority, though those actions produced limited documented reductions in fentanyl precursor flows.
Passed